Merck KGaA's Cilengitide, an experimental drug to treat an aggressive type of brain tumor, has failed a large-scale clinical trial, dealing a blow to the German drugmaker's efforts to replenish its pipeline of medicines.
Merck said on Monday patients in a Phase III trial did not live significantly longer when treated with Cilengitide plus chemoradiotherapy.
Dr. Annalisa Jenkins, Head of Global Drug Development and Medical for the Merck Serono division, said the trial results were "disappointing, especially for people who are fighting this devastating and difficult to treat cancer".
And Cilengitide is a targeted drug. It is based on the cyclic peptide cyclo(-RGDfV-), which is selective for αv integrins, which are important in angiogenesis (forming new blood vessels).
New week and a new failure of targeted drugs...
No comments:
Post a Comment